Iris Acquisition Corp
Status: Live Deal
U=S+W/4
W=S@11.5
| IPO Proceeds, $M | $276.00M |
|---|---|
| IPO Date | Mar 5, 2021 |
| CEO | Sumit Mehta |
| Left Lead | Cantor Fitzgerald |
| IPO Cash in Trust | 100.0% |
| SPAC Tenor | 24 + 6 + 6 + 6 + 3 |
| IPO Sector |
General
Not specified |
| IPO Geography | Global |
| Target Company | Liminatus Pharma |
| Deal Announced | Nov 30, 2022 |
| Deal Size, $M | $175.00M |
| Deal Sector | Healthcare |
| Deal Geography | US/Canada |
| SEC Filings | www.sec.gov |
| Approval Vote | TBD |
| Amendment Vote | Sep 5, 2024 |
IRAA
IRAAU
IRAAW
| Price | $11.00 |
|---|---|
| Last closing price | $11.05 |
| H/L, today | $10.94 / $10.95 |
| H/L, 52-week | $9.70 / $11.22 |
| Volume, today | 70 |
| Volume, 3-month avg. | N/A |
Sign up for Free Trial
No credit card required
Sign in for more on Iris Acquisition Corp:
- Structure and cap table
- 7 directors & officers
- 40 filings and events
- 1 underwriters
Structure
Sign in to view structure, cap table, and calendar of events.
Team
| Name | Age | Title |
|---|---|---|
| Sumit Mehta | 38 | Chief Executive Officer |
| Rohit Nanani | 46 | Chairman & Director |
| Lisha Parmar | Chief Financial Officer | |
| Omkar Halady | Vice President | |
| Richard Peretz | 59 | Director |
| Manish Shah | Director | |
| Nicholas Fernandez | 39 | Director |
Sign in to view team biographies and more sponsor and affiliate data.
Advisors
Underwriters
| Cantor Fitzgerald | BR | 24,000,000 | units |
| 24,000,000 | units | ||
| Up-Front UW fee | 2.00 | % | |
| Deferred UW fee |
3.50 | % |
Sign in to view more advisor data.